Health News: [diabetes ]: Actos Bladder Cancer Lawsuits Help: Resource4thePeople Reports Number of Consolidated Federal Cases Climbs to over 2,500

Yahoo! Health   |  My alerts   |   Edit Alert Monday, Sep 02, 2013 04:11 AM EDT

Health News : diabetes - News from Yahoo !   Onglyza® (saxagliptin) Achieves Primary Safety Endpoint, Demonstrating No Increased Risk for Cardiovascular Death ... Sun, 01 Sep, 2013 11:00 PM PDT AstraZeneca and Bristol-Myers Squibb Company today announced the full results of the SAVOR clinical trial in 16,492 adult patients with type 2 diabetes at high risk for cardiovascular events. Continue reading

Health News : diabetes - News from other sources.   Actos Bladder Cancer Lawsuits Help: Resource4thePeople Reports Number of Consolidated Federal Cases Climbs to over 2,500 Mon, 02 Sep, 2013 12:19 AM PDT Judge in multidistrict litigation also schedules key hearing. As consolidated federal cases move forward Resource4thePeople continues offer of free consultations to consumers seeking compensation over allegations that use of diabetes drug can lead to bladder cancer. (PRWeb September 02, 2013) Read the ... Continue reading Doctors get good and bad safety news on diabetes drugs Sun, 01 Sep, 2013 11:41 PM PDT AMSTERDAM (Reuters) - Diabetes pills known as DPP-4 therapies got a mixed safety report on Monday as studies showed they did not raise the risk of heart attacks but might be linked to heart failure, where the heart fails to pump blood adequately. Continue reading European Society of Cardiology: Hot Line III - Late Breaking Trials on Risk factors and Diabetes Sun, 01 Sep, 2013 11:28 PM PDT WASHINGTON--(BUSINESS WIRE)--Dear Press member, Please find here the links (live at 08:00 CEST) to press releases from the ESC Press Conference on ESC Congress 2013: Hot Line III - Late Breaking Trials on Risk factors and Diabetes: http://www.escardio.org/about/press/press-releases/esc13-amsterdam/Page... Continue reading Treatment with the anti-diabetic drug alogliptin does not increase CV risk in patients with ACS Sun, 01 Sep, 2013 11:24 PM PDT ( European Society of Cardiology ) Patients with Type 2 diabetes and high cardiovascular risk due to recent acute coronary syndromes had similar rates of cardiovascular events when treated with the anti-diabetic agent alogliptin compared to placebo according to results of the Examination of Cardiovascu... Continue reading Takeda EXAMINE Cardiovascular Safety Outcomes Trial of Alogliptin Met Primary Endpoint of Non-Inferiority Compared to ... Sun, 01 Sep, 2013 11:15 PM PDT AMSTERDAM, The Netherlands and OSAKA, Japan, Sept. 2, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) today announced results of the EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and... Continue reading Cardiovascular Outcome Studies in Diabetes Drugs Finally Arrive Sun, 01 Sep, 2013 11:09 PM PDT For many years critics have bemoaned the absence of outcome studies for the many diabetes drugs used to lower blood glucose levels. Now, finally, two large trials with different drugs have been presented at the European Society of Cardiology meeting in Amsterdam and published simultaneously in The New ... Continue reading Walk to defeat diabetes Sun, 01 Sep, 2013 10:08 PM PDT LOCKPORT - The Order of the Amaranth, Tiadaghton Court #136 and Dunnstown Fire Co. Station 5 are teaming up together to sponsor a walk and a chicken barbeque to raise money to "DeFeet Diabetes." The event will be held from 10 a.m. to 4 p.m. Continue reading Fresh fruit deters diabetes; juice boosts risk Sun, 01 Sep, 2013 09:38 PM PDT Even if the nutritional values of whole fruit and fruit juice are similar, the difference lies with the fact that one food is a semi-solid and the other a liquid. Continue reading

You received this email because you subscribed to Yahoo! Alerts. Use this link to unsubscribe from this alert. To change your communications preferences for other Yahoo! business lines, please visit your Marketing Preferences. To learn more about Yahoo!'s use of personal information, including the use of web beacons in HTML-based email, please read our Privacy Policy. Yahoo! is located at 701 First Avenue, Sunnyvale, CA 94089.